KZIA earnings date and last-quarter result: next report 2026-09-04, last quarter miss, P/E -2.01. Updated 2026-07-23.
Kazia Therapeutics (KZIA) Research Hub
Kazia Therapeutics (KZIA) trades on NASDAQ, AU in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 7.87 USD (+0.77%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.01, market cap 0.02B. This hub links to the full technical, earnings and options research available for KZIA.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, AU |
| Last close | 7.87 USD (+0.77%) |
| 52-week range | 6.63 USD – 15.5 USD |
| Trend regime | Range |
| 14-day RSI | 35.7 (Bearish) |
| Trailing P/E | -2.01 |
| Market cap | 0.02B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-04 |
Available research for KZIA
Covered Call on KZIA: how it works, illustrative setup around the real 7.87 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on KZIA: how it works, illustrative setup around the real 7.87 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on KZIA: how it works, illustrative setup around the real 7.87 USD price, max profit/loss, breakeven and when to use it. Educational.
KZIA technical analysis: range, last 7.87 USD, RSI 35.7, 52w range 6.63 USD–15.5 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is KZIA in?
Kazia Therapeutics (KZIA) is classified under Healthcare (Biotechnology), listed on NASDAQ, AU.
Is KZIA in an uptrend or downtrend?
As of 2026-10-26, KZIA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is KZIA's trailing P/E ratio?
KZIA's trailing P/E is -2.01, with a market cap of 0.02B. See the earnings research page for full valuation detail.
When does KZIA next report earnings?
KZIA is next scheduled to report earnings on 2026-09-04.